Parkinsons Disease Flashcards

1
Q

toxic/environmental factors

A

rural living, drinking well water, and exposure to heavy metals, hydrocarbons, pesticides, and/or herbicides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

early onset vs. late onset

A

early onset most likely due to genetics
late onset implies cumulative exposure to putative toxins, CNS aging, and other cell death mechanisms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How do the neurotoxins affect dopamine?

A

MPTP is converted to MPP+ which causes the destruction of dopamine neurons

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

PINK1 genetic mutation

A

produces alterned PTEN induced putative kinase 1 which results in mitochondrial dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

PRKN genetic mutation

A

produces altered protein Parkin resulting in proteosomal dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

LRRK2 gene mutation

A

produces altered protein dardarin resulting in altered protein-protein interactions (late-onset)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

SNCA gene alteration

A

produces misfolded alpha-synuclein causing aggregation and formation of Lewy bodies (early onset)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

GBA gene alteration

A

produces altered protein glucocerobosidase resulting in alterations in lysosomal function and decreased clearance of misfolded proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

various PD pathogenic mechanisms

A

abnormal apoptosis/autophagy, excitotoxicity, inflammation, nitric oxide toxicity, and oxyradicals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Hallmark change

A

loss of dopamine projections from the Substantia Nigra to the striatum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Presence of Lewy bodies in various of the brain

A
  • activation of TLR1/2 on microglia results in activation of the inflammasome causing release of inflammatory cytokines; involved in protein misfolding and altered autophagy
  • alpha-synuclein stimulates NO synthase causing DNA damage and activation of PARP-1 leading to PAR-induced cell death
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

PAR

A

PAR normally repairs DNA
in parkinsons it also binds with preformed fibrils (PFF) contributing to additional alpha-synuclein misfolding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

D1 pathway

A

direct pathway

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

D2 pathway

A

indirect pathway

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What percentage of neuron loss before clinical manifestations are seen?

A

70-80%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

PD clinical presentation

A

muscle rigidity, resting tremor abolished by movement, bradykinesia, and postural instability

17
Q

Carbidopa/l-dopa

A

l-dopa is the immediate precursor of dopamine
l-dopa can cross the BBB by a large neutral amino acid transporter, but carbidopa does not cross the BBB it just prevents peripheral conversion of l dopa

18
Q

how is ldopa converted to dopamine

A

in the SNc by l-amino acid decarboxylase

19
Q

What is dopamine metabolized by

A

MAO-B and COMT

20
Q

“off” periods

A

poor movement including return of tremor, rigidity, or slowness as well as dystonias (sustained muscle contractions)
- also related to increasing loss of neuronal storage capability for DA

21
Q

“on” periods

A

good movement

22
Q

anticholinergics

A

Benztropine and Trihexyphenidyl
effective against tremor caused by increased cholinergic activity as a result of decreased dopamine inhibition of striatal cholinergic interneurons

23
Q

amantadine MOA

A

likely due to enhancement of dopamine release from presynaptic nerve terminals and noncompetitive inhibition of glutamate NMDA receptors; the latter effect appears to predominate
used primarily for management of l-dopa-induced dyskinesias

24
Q

MAO-B inhibitors

A

Rasagiline, Selegiline, Safinamide
selective inhibitors of MAO-B in the brain prolonging dopaminergic activity by extending the effects of l-dopa

25
Q

which MAO-B inhibitors are irreversable?

A

Rasagiline and Selegiline

26
Q

What is Selegiline metabolized to?

A

l-methamphetamine and l-amphetamine
causes multiple neuropsychiatric adverse effects

27
Q

Catechol-O-Methyltransferase Inhibitors (COMTi)

A

entacapone, tolcapone, opicapone
extends the effects of l-dopa by reducing the peripheral conversion of l-dopa to 3-O-methyl DOPA which enhances the bioavailability of central l-dopa
MUST ADMINISTER WITH L-DOPA ADD ON THERAPY

28
Q

Which COMTi can you take just once a day and not with l-dopa dose?

A

Opicapone

29
Q

Tolcapones differences

A

it inhibits both peripheral and central COMT but has limited use due to fatal hepatotoxicity

30
Q

Dopamine Agonists

A

Apomorphine, Bromocriptine, Pramipexole, Ropinorole, Rotigotine
can be used as monotherapy and has signicantly reduced risk of developing motor complications

31
Q

Pimavanserin MOA

A

5HT2A inverse agonist and antagonist
especially for those with delusions and hallucinations

32
Q

Istradefylline MOA

A

Selective adenosine A2 antagonist
- non dopaminergic add on for “off” episodes in patients recieving carbidopa/levidopa